Literature DB >> 18825315

Inhibition of invasion-associated thromboxane synthase sensitizes experimental gliomas to gamma-radiation.

Anne Katrin Schauff1, Ella L Kim, Jan Leppert, Roger Nadrowitz, Robin Wuestenberg, Mark Alexander Brockmann, Alf Giese.   

Abstract

The invasion- and apoptosis-associated thromboxane synthase gene encoding an enzyme of the arachidonic acid pathway has been implicated in glioma progression. Furegrelate, a specific inhibitor of thromboxane synthase, blocks cell motility, induces apoptosis and increases sensitivity to drug induced apoptosis in human glioma cells in vitro. The impact of furegrelate on the sensitivity of human glioma cells to gamma-irradiation was analyzed using colony formation assay in vitro and an orthotopic mouse model in vivo. Pre-treatment of glioma cells with furegrelate increases radiation sensitivity of cultured glioma cells. Treatment of experimental gliomas with suboptimal doses of radiation and furegrelate results in a significant decrease in tumor volumes compared to untreated controls. Thus, the specific thromboxane synthase inhibitor furegrelate increases death response induced by gamma-radiation in glioma cells in vitro and sensitizes experimental gliomas to radiation treatment in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18825315     DOI: 10.1007/s11060-008-9708-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

1.  In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations.

Authors:  Uma Raju; Eiko Nakata; Peiying Yang; Robert A Newman; Kian K Ang; Luka Milas
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-11-01       Impact factor: 7.038

2.  Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathways.

Authors:  S Rodrigues; Q D Nguyen; S Faivre; E Bruyneel; L Thim; B Westley; F May; G Flatau; M Mareel; C Gespach; S Emami
Journal:  FASEB J       Date:  2001-07       Impact factor: 5.191

3.  Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer.

Authors:  Omar Moussa; John S Yordy; Hassan Abol-Enein; Debajyoti Sinha; Nabil K Bissada; Perry V Halushka; Mohamed A Ghoneim; Dennis K Watson
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

4.  Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy.

Authors:  D K Gaffney; J Holden; M Davis; K Zempolich; K J Murphy; M Dodson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-04-01       Impact factor: 7.038

5.  Role of cyclooxygenase-2 inhibitors in combination with radiation therapy in lung cancer.

Authors:  Zhongxing Liao; Ritsuko Komaki; Kathryn A Mason; Luka Milas
Journal:  Clin Lung Cancer       Date:  2003-05       Impact factor: 4.785

6.  Determinants of human astrocytoma migration.

Authors:  A Giese; M D Rief; M A Loo; M E Berens
Journal:  Cancer Res       Date:  1994-07-15       Impact factor: 12.701

7.  Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis.

Authors:  J Jantke; M Ladehoff; F Kürzel; S Zapf; E Kim; A Giese
Journal:  Acta Neurochir (Wien)       Date:  2004-04-13       Impact factor: 2.216

8.  Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1.

Authors:  Ella Kim; Willy Günther; Kimio Yoshizato; Hildegard Meissner; Srenja Zapf; Rolf M Nüsing; Hirotaka Yamamoto; Erwin G Van Meir; Wolfgang Deppert; Alf Giese
Journal:  Oncogene       Date:  2003-10-30       Impact factor: 9.867

Review 9.  Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: preclinical basis.

Authors:  Luka Milas
Journal:  Am J Clin Oncol       Date:  2003-08       Impact factor: 2.339

Review 10.  The biology of the Ets1 proto-oncogene.

Authors:  Jürgen Dittmer
Journal:  Mol Cancer       Date:  2003-08-20       Impact factor: 27.401

View more
  9 in total

Review 1.  Cyclooxygenases and lipoxygenases in cancer.

Authors:  Claus Schneider; Ambra Pozzi
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 2.  The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis.

Authors:  Prasanna Ekambaram; Wanyu Lambiv; Rosanna Cazzolli; Anthony W Ashton; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

3.  αB-crystallin is elevated in highly infiltrative apoptosis-resistant glioblastoma cells.

Authors:  Dorota Goplen; Sébastien Bougnaud; Uros Rajcevic; Stig O Bøe; Kai O Skaftnesmo; Juergen Voges; Per Ø Enger; Jian Wang; Berit B Tysnes; Ole D Laerum; Simone Niclou; Rolf Bjerkvig
Journal:  Am J Pathol       Date:  2010-09-02       Impact factor: 4.307

4.  Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy.

Authors:  Nils Ole Schmidt; Mateo Ziu; Theresa Cargioli; Manfred Westphal; Alf Giese; Peter M Black; Rona S Carroll
Journal:  Transl Oncol       Date:  2010-02       Impact factor: 4.243

5.  ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration.

Authors:  Guido Fròsina; Aldo Profumo; Daniela Marubbi; Diana Marcello; Jean Louis Ravetti; Antonio Daga
Journal:  Radiat Oncol       Date:  2018-04-23       Impact factor: 3.481

6.  Eicosanoids and cancer.

Authors:  Renata Nascimento Gomes; Souza Felipe da Costa; Alison Colquhoun
Journal:  Clinics (Sao Paulo)       Date:  2018-08-20       Impact factor: 2.365

Review 7.  The Role and Regulation of Thromboxane A2 Signaling in Cancer-Trojan Horses and Misdirection.

Authors:  Anthony W Ashton; Yunjia Zhang; Rosanna Cazzolli; Kenneth V Honn
Journal:  Molecules       Date:  2022-09-22       Impact factor: 4.927

Review 8.  A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

Authors:  Richard E Kast; John A Boockvar; Ansgar Brüning; Francesco Cappello; Wen-Wei Chang; Boris Cvek; Q Ping Dou; Alfonso Duenas-Gonzalez; Thomas Efferth; Daniele Focosi; Seyed H Ghaffari; Georg Karpel-Massler; Kirsi Ketola; Alireza Khoshnevisan; Daniel Keizman; Nicolas Magné; Christine Marosi; Kerrie McDonald; Miguel Muñoz; Ameya Paranjpe; Mohammad H Pourgholami; Iacopo Sardi; Avishay Sella; Kalkunte S Srivenugopal; Marco Tuccori; Weiguang Wang; Christian R Wirtz; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2013-04

Review 9.  Contemporary Mouse Models in Glioma Research.

Authors:  William H Hicks; Cylaina E Bird; Jeffrey I Traylor; Diana D Shi; Tarek Y El Ahmadieh; Timothy E Richardson; Samuel K McBrayer; Kalil G Abdullah
Journal:  Cells       Date:  2021-03-23       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.